A 68-year-old woman with a history of chronic lymphocytic leukemia (CLL) is started on rituximab (anti-CD20 monoclonal antibody) as part of her chemotherapy regimen. Two weeks into treatment, bone marrow biopsy shows a marked reduction in CD20+ B lymphocytes. Histological examination reveals that the leukemic cells are undergoing programmed cell death with the following features: cell shrinkage, chromatin condensation (pyknosis), fragmentation into membrane-bound apoptotic bodies, and absence of inflammatory cell infiltration. Serum LDH is normal and phosphate levels are stable. Which mechanism best explains the therapeutic effect of rituximab on the CLL cells?

Explanation

## Rituximab-Induced Cell Death in CLL: Apoptosis vs Necrosis The clinical and histological findings in this case are diagnostic of **apoptosis**, not necrosis. Rituximab induces programmed cell death in CD20+ B lymphocytes through multiple mechanisms. ### Characteristics of Apoptosis Observed in This Case **Key Point:** The histological hallmarks of apoptosis are clearly present: - **Cell shrinkage (pyknosis)** — cytoplasm becomes dense and basophilic - **Chromatin condensation** — DNA fragments into 180–200 base pair multiples - **Membrane-bound apoptotic bodies** — cell fragments remain enclosed, preventing leakage - **Absence of inflammatory infiltrate** — apoptotic cells are "silent" and rapidly phagocytosed - **Normal LDH and phosphate** — no cell lysis or tumor lysis syndrome ### Mechanisms of Rituximab-Induced Apoptosis ```mermaid flowchart TD A[Rituximab binds CD20]:::action --> B{Mechanism?}:::decision B -->|ADCC| C[NK cells, macrophages recruited]:::action B -->|CDC| D[Complement cascade activated]:::action B -->|Direct| E[Cross-linking CD20]:::action C --> F[Perforin/granzyme release]:::action D --> F E --> F F --> G[Caspase activation]:::action G --> H[Apoptosis: pyknosis, fragmentation]:::outcome H --> I[Phagocytosis by macrophages]:::action I --> J[No inflammation, normal labs]:::outcome ``` **High-Yield:** Rituximab induces apoptosis through three main pathways: 1. **Antibody-Dependent Cellular Cytotoxicity (ADCC)** — NK cells and macrophages recognize the Fc portion of rituximab and release cytotoxic granules (perforin, granzyme B) 2. **Complement-Dependent Cytotoxicity (CDC)** — rituximab activates the classical complement pathway, forming the membrane attack complex 3. **Direct cross-linking** — rituximab cross-links CD20 molecules, triggering intrinsic apoptotic pathways ### Comparison: Apoptosis vs Necrosis in Hematologic Malignancies | Feature | Apoptosis (Rituximab) | Necrosis (Tumor Lysis) | |---------|----------------------|----------------------| | **Cell Size** | Shrinkage | Swelling | | **Chromatin Pattern** | Condensation, fragmentation | Disrupted | | **Membrane Integrity** | Preserved in apoptotic bodies | Lost | | **Inflammation** | Absent (silent death) | Intense | | **LDH Release** | Minimal | Marked elevation | | **Phosphate/Potassium** | Normal | Elevated (TLS) | | **Phagocytosis** | Rapid, clean | Delayed, messy | | **Clinical Consequence** | Tumor regression without toxicity | Acute kidney injury, arrhythmias | **Clinical Pearl:** The absence of tumor lysis syndrome (normal LDH and phosphate) is a crucial diagnostic clue that apoptosis is occurring. If rituximab caused necrosis with massive cell lysis, we would expect hyperkalemia, hyperphosphatemia, elevated LDH, and acute kidney injury — none of which are present. ### Why Apoptosis Is Therapeutically Favorable **Key Point:** Apoptosis is the preferred mechanism of cancer cell death because: - Apoptotic bodies remain membrane-bound, preventing spillage of intracellular contents - No inflammatory response that could promote tumor growth or metastasis - Rapid clearance by phagocytes without tissue damage - No acute complications (unlike necrosis-induced tumor lysis syndrome) **Mnemonic:** **APOPTOSIS = Antibody-mediated, Programmed, Organized, Pyknosis, Tiny fragments, Orderly, Silent, Inner caspases, Silent inflammation**